Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Ranitidine HCl (ZANTAC; AH-19065; AH 19065; Tanidina; Toriol; Fendibina; Gastridina; Sostril; Zantic; Ranisen), the hydrochloride salt of Ranitidine, is a histamine H2-receptor antagonist with an IC50 of 3.3 ± 1.4 uM. Through the inhibition of stomach acid production, it is used to treat ulcers in the stomach or intestines. While ranitidine HCl does not have this property, it makes hepatocytes more vulnerable to death from cytotoxic products produced by activated neutrophils. When lipopolysaccharide is used to stimulate monocytes in vitro, ranitidine prevents the production of tumor necrosis factor-alpha (TNF-alpha).
Targets |
Histamine H2 receptor
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C13H23CLN4O3S
|
|
---|---|---|
Molecular Weight |
350.86
|
|
Exact Mass |
350.12
|
|
Elemental Analysis |
C, 44.50; H, 6.61; Cl, 10.10; N, 15.97; O, 13.68; S, 9.14
|
|
CAS # |
66357-59-3
|
|
Related CAS # |
Ranitidine-d6 hydrochloride; 1185238-09-8; Ranitidine; 66357-35-5; Ranitidine bismuth citrate; 128345-62-0
|
|
Appearance |
Solid powder
|
|
SMILES |
CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C.Cl
|
|
InChi Key |
GGWBHVILAJZWKJ-KJEVSKRMSA-N
|
|
InChi Code |
InChI=1S/C13H22N4O3S.ClH/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3;/h4-5,9,14-15H,6-8,10H2,1-3H3;1H/b13-9+;
|
|
Chemical Name |
(E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.93 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.93 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 110 mg/mL (313.52 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8501 mL | 14.2507 mL | 28.5014 mL | |
5 mM | 0.5700 mL | 2.8501 mL | 5.7003 mL | |
10 mM | 0.2850 mL | 1.4251 mL | 2.8501 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01131702 | Completed | Drug: Ranitidine | Healthy | Dr. Reddy's Laboratories Limited | January 2003 | Phase 1 |
NCT04397445 | Completed | Drug: Ranitidine Drug: Placebo Other: Low nitrite/NDMA meals |
Ranitidine Adverse Reaction Pharmacokinetics Food-drug Interaction |
Food and Drug Administration (FDA) |
June 8, 2020 | Phase 1 |
NCT01896557 | Completed | Drug: omeprazole Drug: Ranitidine Drug: Clopidogrel |
Coronary Artery Disease Drug Interaction Potentiation |
University of Sao Paulo General Hospital |
October 2011 | Phase 4 |
NCT02197143 | Completed | Drug: esomeprazole Drug: Ranitidine |
Dyspepsia | Pamukkale University | March 2013 | Phase 4 |
NCT01737840 | Completed | Drug: Pantoprazole Drug: Ranitidine |
Dyspepsia | Akdeniz University | October 2012 | Phase 4 |